We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IL-23

News List

Risankizumab trials show higher clinical remission in patients with Crohn’s disease europeanpharmaceuticalreview
January 12, 2021
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn’s disease.
Janssen’s psoriasis med Tremfya scores long-term safety and efficacy data pharmatimes
October 19, 2020
Janssen has announced new open-label extension data for Tremfya, with the treatment continuing to show high rates of skin clearance through nearly five years in moderate to severe plaque psoriasis.
Innovent Announces First Subject Dosed in Trial of Anti-IL-23 Monoclonal Antibody americanpharmaceuticalreview
September 02, 2020
Innovent Biologics announced the Phase I clinical study (CIBI112A101) of recombinant anti-interleukin 23p19 subunit antibody injection (IBI112) has completed the first healthy subject dosing in China.